💡 Personal treatment efficacy tracker with regional resistance intelligence

[github-actions[bot]]

Summary

Track individual treatment efficacy through prompted paired mite counts (pre-treatment and 14-day post-treatment), automatically calculate efficacy percentages, and alert beekeepers when their treatment performance drops below expected benchmarks. As user density grows, aggregate anonymized efficacy data by region and treatment type to detect emerging resistance patterns — particularly the developing Amitraz resistance crisis — and proactively recommend treatment switches before losses occur.

Market Signal

Amitraz resistance in varroa mites is now documented in peer-reviewed research (2025), threatening the primary chemical treatment used by the majority of commercial and hobbyist beekeepers. 2024-2025 saw record colony losses: 55.6% annual and 40.2% winter (Bee Informed Partnership / Apiary Inspectors of America). BroodMinder tracks some treatment data but doesn't calculate efficacy percentages or alert on declining treatment performance. HiveSense has no treatment analytics capabilities. The Bee Informed Partnership publishes population-level loss data but no app provides individual treatment efficacy tracking with actionable, personalized alerts. This represents a critical gap as the Amitraz resistance crisis accelerates.

User Signal

Existing ideas #348 (automated treatment efficacy scoring from paired mite counts) and #85 (treatment compliance, PHI alerts & efficacy scoring) address related concerns. However, neither specifically targets the RESISTANCE detection pattern — identifying when a treatment that used to work for a specific beekeeper is losing effectiveness — nor the regional intelligence angle of crowdsourcing resistance patterns across geographic zones. The PRD's treatment tracking requirements (FR16) and the recommendation engine's confidence framework support treatment efficacy as a first-class signal in the decision pipeline. Paired mite count methodology is standard beekeeping practice — the gap is automated efficacy calculation, trend visualization, and proactive alerting.

Technical Opportunity

The treatment and inspection schemas already support mite count observations (Story 3.2). Adding a paired_count relationship between pre-treatment and post-treatment mite counts is a straightforward schema extension. Efficacy calculation (1 - post/pre × 100) is trivially computed. Regional aggregation leverages the existing regional context infrastructure and the analytics data layer specified in the architecture document (separate anonymized analytical store optimized for aggregation queries). The alert mechanism uses the existing notification dispatch infrastructure via Cloud Pub/Sub. Anonymous data sharing respects the privacy controls already designed into the RBAC and consent model.

Assessment

Dimension	Score	Rationale
Feasibility	high	Simple schema extension to existing treatment/mite count data. Efficacy calculation is trivial. Regional aggregation uses planned analytics infrastructure.
Impact	high	Directly addresses emerging Amitraz resistance crisis. Unique capability — no competitor provides personalized treatment efficacy tracking with decline alerts. Could prevent significant colony losses through earlier treatment switching.
Urgency	high	Amitraz resistance is documented and accelerating (2025 research). Record colony losses (55.6%) make treatment optimization critically urgent. Every season of delayed action compounds resistance spread.

Adversarial Review

Strongest objection: Regional resistance intelligence requires massive user density to be statistically meaningful. A new app with few users will produce noisy, unreliable regional signals that could cause beekeepers to switch treatments unnecessarily — potentially replacing a still-effective treatment with a less suitable alternative.

Rebuttal: The feature is designed in two phases precisely to address this. Phase 1 delivers individual value without any network effect — personal treatment efficacy tracking and benchmarking against published research baselines (not crowdsourced data). A beekeeper seeing 'Your Amitraz efficacy has dropped from 92% to 68% over two consecutive treatments' is immediately actionable regardless of what anyone else's data shows. Regional intelligence is Phase 2, activated only when user density in a geographic zone crosses a configurable statistical significance threshold. Until that threshold is met, users see only their personal data and published benchmark comparisons. This phased approach ensures the feature never produces misleading regional signals.

Suggested Next Step

Define the paired mite count data model (pre_treatment_count, post_treatment_count, treatment_type, treatment_date, days_between_counts, efficacy_ratio). Design the treatment efficacy dashboard card following the HiveHealthCard pattern with decline trend visualization. Define efficacy threshold alerts by treatment type (e.g., Amitraz efficacy below 85% triggers a 'consider alternatives' recommendation with specific alternative suggestions). Research and catalog published efficacy benchmarks by treatment type for MVP baseline comparisons.